| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.3 | 6e-06 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.17 | 8e-06 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | -0.16 | 1e-05 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.14 | 1e-05 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | -0.17 | 1e-05 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.15 | 1e-05 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-05 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-05 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-05 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-05 |